Kenvue, Inc. KVUE

Kimberly-Clark has had a rough stretch in the market over the past year, and that weak share performance puts fresh focus on one core issue: whether the current price around US$97 is sensible when you line it up against the cash the business is expected to generate. With investors also watching the pending Kenvue acquisition and related financing steps, the key question now is how those moves feed into the long term cash flow story behind the stock. The share price has fallen 16.5% over the...

Kimberly-Clark (NasdaqGS:KMB) has launched exchange offers and consent solicitations for Kenvue's outstanding notes tied to its pending acquisition. The proposal gives Kenvue bondholders the option to swap existing securities into new Kimberly-Clark issued notes subject to specified terms. The consent solicitations seek bondholder approval to amend certain covenants in Kenvue's current debt documents as part of the transaction process. Kimberly-Clark's move to exchange and amend Kenvue notes...

Kimberly-Clark just logged its 54th straight year of dividend increases, but a shrinking raise, falling free cash flow, and a massive acquisition in progress raise a pointed question for income investors living on those checks.

Rising rates have boomers flocking to Treasuries, but five battle-tested dividend payers with 50-plus years of consecutive increases may offer something bonds simply cannot deliver.

VIENNA, September 30, 2026--Neutrogena®, Aveeno®, and Regaine®* will present 12 new scientific data sets at the 35th European Academy of Dermatology and Venereology (EADV) Congress taking place September 30th through October 3rd in Vienna.

Kimberly-Clark has raised its dividend through every recession of the past two decades, but a $48.7 billion acquisition and free cash flow that already fell short of last year's dividend payment put that streak in genuine jeopardy.

Kimberly-Clark Corporation (NASDAQ: KMB) ("Kimberly-Clark") announced today the commencement, in connection with its previously announced pending acquisition ("Acquisition") of Kenvue Inc. (NYSE: KVUE) ("Kenvue"), of an exchange offer (each an "Exchange Offer" and, collectively, the "Exchange Offers") for any and all outstanding notes (the "Kenvue Notes") issued by Kenvue for up to $7,000,000,000 aggregate principal amount of new notes to be issued by Kimberly-Clark (the "Kimberly-Clark Notes")

Kimberly-Clark hands retirees a fatter dividend check every quarter, but one look at what sits behind that payout changes the picture fast. Before you choose the bigger yield, consider what happens when the income has to last decades.

Kimberly-Clark just logged 54 straight years of dividend raises, but a closer look at the cash flow statement raises an uncomfortable question about who is actually funding that growing payout.

While investors pile into pricey AI darlings, a handful of battle-tested Dividend Kings have quietly slipped to levels that scream value, and Wall Street analysts see serious upside ahead for 2027.

This article first appeared on GuruFocus. Kenvue Inc (NYSE:KVUE) recently announced a total dividend of $0.21 per share, with the ex-dividend date set for 2026-09-21. For income-focused investors, the ex-dividend date is a critical marker: shareholders must own the stock before this date to qualify for the payment.

Kimberly-Clark (NasdaqGS:KMB) plans to sell assets tied to its planned US$40b acquisition of consumer products group Kenvue. The disposals are aimed at addressing European Union antitrust concerns linked to overlaps in consumer health and personal care brands. Asset sale discussions focus on EU markets where regulators flagged competition issues as part of their ongoing review of the Kenvue deal. Kimberly-Clark's move to sell assets around the US$40b Kenvue deal sits within a broader pattern...

Younger investors are rewriting the rules of wealth building, and five overlooked dividend stocks under $20 sit right at the center of that shift. The real question is whether these picks can hold up long enough to matter.

Kenvue Inc. previously announced that its Board of Directors declared a quarterly dividend of US$0.21 per share, payable on October 2, 2026, to shareholders of record as of September 21, 2026, while also securing FDA approval for TYLENOL with Naproxen, a first-of-its-kind non-opioid OTC pain reliever backed by multiple clinical studies. By pairing a new, clinically supported TYLENOL with Naproxen launch with ongoing cash returns via dividends, Kenvue is highlighting both product innovation...

Kenvue (KVUE) is on investors’ radar after launching TYLENOL with Naproxen, an FDA-approved, opioid-free over the counter pain reliever that combines acetaminophen and naproxen sodium, backed by extensive clinical research. That launch comes as Kenvue’s share price has softened in the short term, with a 7 day share price return of down 4.43% and a 30 day share price return of down 6.72%. Even though the year to date share price return is 3.41% and the 1 year total shareholder return is 2.85%,...

Kimberly-Clark Corporation (NASDAQ:KMB) is preparing asset sales to address EU antitrust concerns surrounding its planned $40 billion acquisition of Kenvue, according to Reuters. The company is reportedly seeking to offer remedies that could secure European Commission approval by the September 29 deadline, avoiding a more extensive four-month investigation. Similar regulatory concerns have already emerged in […]

Consumer stocks were mixed late Monday afternoon, with the State Street Consumer Staples Select Sect